Current Report Filing (8-k)
December 10 2019 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 10, 2019
FIBROCELL SCIENCE, INC.
(Exact Name of Registrant as Specified in
its Charter)
DELAWARE
|
001-31564
|
87-0458888
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
405 EAGLEVIEW BLVD., EXTON, PA 19341
(Address of principal executive offices
and zip code)
(484) 713-6000
(Registrant’s telephone number, including
area code)
(Former
name or former address, if changed from last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par value $0.001
|
FCSC
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07. Submission of Matters to a Vote
of Security Holders.
Fibrocell Science, Inc. (the “Company”)
held a special meeting of stockholders on December 10, 2019 (the “special meeting”). At the special meeting,
the Company’s stockholders approved the two proposals described below. Stockholder action on a third proposal, to approve
one or more adjournments of the special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient
votes to approve proposal 1, was not required and no vote was taken on that proposal.
The final voting results with respect to
each proposal voted upon at the special meeting are set forth below.
Proposal 1
The Company’s stockholders adopted
the Agreement and Plan of Merger, dated as of September 12, 2019 (the “Merger Agreement”), by and among the Company,
Castle Creek Pharmaceutical Holdings, Inc., a Delaware corporation (“Castle Creek”) and Castle Creek Merger Corp.,
a Delaware corporation and a wholly-owned subsidiary of Castle Creek (“Merger Sub”), as it may be amended from time
to time, pursuant to which Merger Sub will merge with and into the Company, with the Company surviving the Merger as a wholly-owned
subsidiary of Castle Creek (the “Merger”), and holders of common stock, par value $0.001 per share, of the Company
(“Common Stock”) will be entitled to receive $3.00 in cash, without interest and less any applicable withholding taxes,
for each share of Common Stock that they own immediately prior to the effective time of the Merger, as set forth below:
For
|
|
Against
|
|
Abstentions
|
|
Broker Non-Votes
|
6,980,096
|
|
35,825
|
|
7,228
|
|
0
|
Proposal 2
The Company’s stockholders approved,
on a non-binding, advisory basis, the compensation that will or may become payable to the Company’s named executive officers
in connection with the Merger, as set forth below:
For
|
|
Against
|
|
Abstentions
|
|
Broker Non-Votes
|
6,884,515
|
|
93,610
|
|
45,024
|
|
0
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
|
|
Fibrocell Science, Inc.
|
|
|
|
|
By:
|
/s/ John M. Maslowski
|
|
|
John M. Maslowski
|
|
|
President and Chief Executive Officer
|
Date: December
10, 2019
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Apr 2023 to Apr 2024